ArticleBMC pulmonary medicine2025
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Recurrent Pleural Solitary Fibrous Tumor: A Case Report and Brief Literature Review.Reports (MDPI) · 2026Article
- Perioperative Decision-Making for a Solitary Fibrous Tumor of the Pleura: Lessons from Two Cases and Current Evidence.Diagnostics (Basel, Switzerland) · 2026Article
- Effectiveness of classification and scoring systems in solitary fibrous tumor prognosis prediction.Pakistan journal of medical sciences · 2026Article
- FDG-PET/CT SUVmax Predicts Recurrence Risk of Resected Pleuropulmonary Solitary Fibrous Tumors.JTO clinical and research reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral studies have been conducted to identify the parameters associated with the aggressive course of pleuropulmonary solitary fibrous tumors (SFT) following surgical treatment, and various classification systems have been proposed for assessing risk.
methodsThe surgical outcomes of patients with pleuropulmonary SFT who underwent surgery between 2009 and 2024 at our center were retrospectively evaluated. Parameters of patients who experienced recurrence during follow-up were analyzed, and the risk classification systems proposed by Demicco were tested on our patient cohort. The pozitron emision tomography/ computed tomography (PET/CT) standart uptake value(SUVmax), which was significantly associated with recurrence, was incorporated into the modified Demicco classification, and a new classification model was developed and compared with existing models.
resultsAmong the 79 included patients, 21.5% had intraparenchymal tumors, which were excised along with various parenchymal resections, while pleural tumors underwent mass excision. The postoperative follow-up period was 108.16 ± 44.09 months, during which 7.6% of patients experienced recurrence. Tumor size (p = 0.023), mitotic index (p < 0.001), presence of necrosis (p = 0.007), and PET/CT SUVmax value (p = 0.005) were found to be significantly associated with recurrence. The PET/CT SUVmax value, which was not included in Demicco's classifications, ranged from 1.12 to 7.98, with a cutoff value of 4.50. The addition of SUVmax to the modified Demicco classification categorized all patients with recurrence into the high-risk group, and the new classification model strongly differentiated recurrence (p < 0.01, 100% sensitivity, 71.43% specificity).
conclusionThe incorporation of SUVmax into the modified Demicco classification system for pleuropulmonary SFT provides a more significant prediction of recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.